2024
The Prognostic Impact of MLH1 Promoter Hypermethylation in Stage I-II Endometrial Cancer Treated with Adjuvant Radiotherapy
Sherwani Z, Damast S, Fields E, Shah S, Beriwal S, Horne Z, Parks E, Kidd E, Leung E, Khoja L, Taunk N, Chino J, Huang C, Russo A, Dyer M, Albuquerque K, Hathout L. The Prognostic Impact of MLH1 Promoter Hypermethylation in Stage I-II Endometrial Cancer Treated with Adjuvant Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s32. DOI: 10.1016/j.ijrobp.2024.07.044.Peer-Reviewed Original ResearchRecurrence-free survivalExternal beam radiationMismatch repair statusOverall survivalAdjuvant radiotherapyVaginal brachytherapyAssociated with decreased RFSPromoter hypermethylationInferior recurrence-free survivalProportion of locoregional recurrenceTreated with adjuvant radiotherapyDepth of myometrial invasionLympho-vascular space invasionMulti-institutional cohort studyRetrospective multi-institutional cohort studyCervical stromal involvementSite of recurrenceKaplan Meier methodPost-surgical resectionCox proportional hazards modelsMulti-institutional studyDeficient mismatch repairProportional hazards modelImpact OSLocoregional recurrence
2022
An evaluation of prognostic factors, oncologic outcomes, and management for primary and recurrent squamous cell carcinoma of the vulva
Li JY, Arkfeld CK, Tymon-Rosario J, Webster E, Schwartz P, Damast S, Menderes G. An evaluation of prognostic factors, oncologic outcomes, and management for primary and recurrent squamous cell carcinoma of the vulva. Journal Of Gynecologic Oncology 2022, 33: 0. PMID: 34910394, PMCID: PMC8899873, DOI: 10.3802/jgo.2022.33.e13.Peer-Reviewed Original ResearchConceptsDisease-specific survivalSquamous cell carcinomaOverall survivalPositive marginsCell carcinomaNodal involvementPrognostic factorsStage IFive-year disease-specific survivalPrimary squamous cell carcinomaRecurrent squamous cell carcinomaFive-year RFSNode-positive patientsVulvar cancer patientsEscalation of treatmentConservative surgical approachKaplan-Meier estimatesLog-rank testCox proportional hazardsLocal RFSOverall RFSAdjuvant radiotherapyDistant recurrenceFree survivalMedian survival
2017
Adjuvant Therapy Use and Survival in Stage II Endometrial Cancer
Lester-Coll NH, Young MR, Park HS, Ratner ES, Litkouhi B, Damast S. Adjuvant Therapy Use and Survival in Stage II Endometrial Cancer. International Journal Of Gynecological Cancer 2017, 27: 1904-1911. PMID: 28763364, DOI: 10.1097/igc.0000000000001095.Peer-Reviewed Original ResearchConceptsReceipt of chemotherapyEndometrioid endometrial carcinomaNational Cancer Data BaseImproved overall survivalRole of chemotherapyOverall survivalAdjuvant chemotherapyAdjuvant treatmentStage II endometrial cancerCox proportional hazards regressionPropensity scoreAdjuvant therapy useGrade 3 diseaseStage II patientsProportional hazards regressionWorse overall survivalMultivariable logistic regressionKaplan-Meier estimatesLog-rank testAdjuvant radiotherapyExcellent prognosisLymphovascular invasionObservational cohortEEC patientsEndometrial cancer